Epidemiology of invasive aspergillosis in China

Abstract

Abstract:

Invasive aspergillosis (IA) is a serious opportunistic infection that mainly been found in individuals with a compromised immune system. As Aspergillus species worldwide and the increasing number of immunocompromised hosts, IA brings a heavy burden to our country. In addition, early diagnosis is difficult and effective treatments are lacking, which leaded to the high mortality of IA (39%~100%). Currently, further nationwide epidemiological research of IA is needed in China.

Key words: aspergillosis, epidemiology, China

CLC Number:

R519.8

XU Yuan, CHEN Min, LIAO Wan-qing. Epidemiology of invasive aspergillosis in China[J]. Chinese Journal of Mycology, 2018, 13(1): 57-60.

References

[1] Krijgsheld P, Bleichrodt R, van Veluw GJ, et al. Development in Aspergillus[J]. Stud Mycol, 2013, 74(1):1-29.
[2] Sharma OP, Chwogule R. Many faces of pulmonary aspergillosis[J]. Eur Respir J, 1998, 12(3):705-715.
[3] Ao JH, Hao ZF, Zhu H, et al. Environmental investigations and molecular typing of Aspergillus in a Chinese hospital[J]. Mycopathologia, 2014, 177(1-2):51-57.
[4] Porpon R, Chen YC, Chakrabarti A, et al. Epidemiology and clinical characteristics of invasive mould infections:A multicenter, retrospective analysis in five Asian countries[J]. Med Mycol, 2017.
[5] Dai Z, Zhao H, Cai S, et al. Invasive pulmonary aspergillosis in non-neutropenic patients with and without underlying disease:a single-centre retrospective analysis of 52 subjects[J]. Respirology, 2013, 18(2):323-331.
[6] Lockhart SR, Frade JP, Etienne KA, et al. Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the cyp51A gene[J]. Antimicrob Agents Chemother, 2011, 55(9):4465-4468.
[7] Denning DW, Pleuvry A,Cole DC. Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults[J]. Med Mycol, 2013, 51(4):361-370.
[8] 陈勇,卢中一,靳远,等.烟曲霉对唑类药物耐药研究的最新进展[J].中华流行病学杂志,2016,37(12):1687-1692.
[9] Brown GD, Denning DW, Gow NA, et al. Hidden killers:human fungal infections[J]. Sci Transl Med, 2012, 4(165):165rv13.
[10] Wang W, Zhao CY, Zhou JY, et al. Invasive pulmonary aspergillosis in patients with HBV-related liver failure[J]. Eur J Clin Microbiol Infect Dis, 2011, 30(5):661-667.
[11] Chen J, Yang Q, Huang J, et al. Clinical findings in 19 cases of invasive pulmonary aspergillosis with liver cirrhosis[J]. Multidiscip Respir Med, 2014, 9(1):1.
[12] Taccone FS, Van den Abeele AM, Bulpa P, et al. Epidemiology of invasive aspergillosis in critically ill patients:clinical presentation, underlying conditions, and outcomes[J]. Crit Care, 2015, 19:7.
[13] Luo BL, Zhang LM, Hu CP, et al. Clinical analysis of 68 patients with pulmonary mycosis in China[J]. Multidiscip Respir Med, 2011, 6(5):278-283.
[14] Chen KY, Ko SC, Hsueh PR, et al. Pulmonary fungal infection:emphasis on microbiological spectra, patient outcome, and prognostic factors[J]. Chest, 2001, 120(1):177-184.
[15] 刘又宁,余丹阳,孙铁英,等.中国1998年至2007年临床确诊的肺真菌病患者的多中心回顾性调查[J].中华结核和呼吸杂志,2011,34(2):86-90.
[16] 高露娟,余进,李若瑜.中国大陆地区曲霉病流行现状分析[J].中国真菌学杂志,2010,5(4):247-251.
[17] Shi JY, Xu YC, Shi Y, et al. In vitro susceptibility testing of Aspergillus spp. against voriconazole, itraconazole, posaconazole, amphotericin B and caspofungin[J]. Chin Med J (Engl), 2010, 123(19):2706-2709.
[18] Zhang M, Feng CL, Chen F, et al. Triazole Resistance in Aspergillus fumigatus clinical isolates obtained in Nanjing, China[J]. Chin Med J (Engl), 2017, 130(6):665-668.
[19] Li Y, Wan Z, Liu W, et al. Identification and susceptibility of Aspergillus section nigri in china:prevalence of species and paradoxical growth in response to echinocandins[J]. J Clin Microbiol, 2015, 53(2):702-705.
[20] Baddley JW, Stroud TP, Salzman D, et al. Invasive mold infections in allogeneic bone marrow transplant recipients[J]. Clin Infect Dis, 2001, 32(9):1319-1324.
[21] Liao WQ, Shao JZ, Li SQ, et al. Mycological identification of pulmonary aspergilloma caused by Aspergillus oryzae with proliferating heads[J]. Chin Med J (Engl), 1988, 101(8):601-604.
[22] Liao WQ, Wen H, Chen YC, et al. The first case of obstructing bronchial aspergillosis caused by Aspergillus sydowi[J]. Int J Infect Dis, 2004, 8(2):132-133.
[23] Chen Y, Lu Z, Zhao J, et al. Epidemiology and molecular characterizations of azole resistance in clinical and environmental Aspergillus fumigatus isolates from China[J]. Antimicrob Agents Chemother, 2016, 60(10):5878-5884.
[24] Liu M, Zeng R, Zhang L, et al. Multiple cyp51A-based mechanisms identified in azole-resistant isolates of Aspergillus fumigatus from China[J]. Antimicrob Agents Chemother, 2015, 59(7):4321-4325.
[25] Verweij PE, Mellado E, Melchers WJ. Multiple-triazole-resistant aspergillosis[J]. N Engl J Med, 2007, 356(14):1481-1483.
[26] van der Linden JW, Camps SM, Kampinga GA, et al. Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles[J]. Clin Infect Dis, 2013, 57(4):513-520.
[27] Chen Y, Wang H, Lu Z, et al. Emergence of TR46/Y121F/T289A in an Aspergillus fumigatus isolate from a Chinese patient[J]. Antimicrob Agents Chemother, 2015, 59(11):7148-7150.
[28] Vermeulen E, Maertens J, Schoemans H, et al. Azole-resistant Aspergillus fumigatus due to TR46/Y121F/T289A mutation emerging in Belgium, July 2012[J]. Euro Surveill, 2012, 17(48).
[29] Hagiwara D, Watanabe A, Kamei K, et al. Epidemiological and genomic landscape of azole resistance mechanisms in Aspergillus fungi[J]. Front Microbiol, 2016, 7:1382.
[30] Liu W, Sun Y, Chen W, et al. The T788G mutation in the cyp51C gene confers voriconazole resistance in Aspergillus flavus causing aspergillosis[J]. Antimicrob Agents Chemother, 2012, 56(5):2598-2603.
[31] Zhang R, Wang S, Lu H, et al. Misdiagnosis of invasive pulmonary aspergillosis:a clinical analysis of 26 immunocompetent patients[J]. Int J Clin Exp Med, 2014, 7(12):5075-5082.
[32] De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group[J]. Clin Infect Dis, 2008, 46(12):1813-1821.
[33] Guinea J, Bouza E. Current challenges in the microbiological diagnosis of invasive aspergillosis[J]. Mycopathologia, 2014, 178(5-6):403-416.
[34] 中华内科杂志编辑委员会.血液病/恶性肿瘤患者侵袭性真菌感染的诊断标准与治疗原则(修订版)[J].中华内科杂志,2007,46(7):607-610.
[35] Chen J, Yang Q, Huang J, et al. Risk factors for invasive pulmonary aspergillosis and hospital mortality in acute-on-chronic liver failure patients:a retrospective-cohort study[J]. Int J Med Sci, 2013, 10(12):1625-1631.
[36] Li D, Chen L, Ding X, et al. Hospital-acquired invasive pulmonary aspergillosis in patients with hepatic failure[J]. BMC Gastroenterol, 2008, 8:32.
[37] Patterson TF, Thompson Ⅲ GR, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis:2016 update by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2016, 63(4):e1-e60.